Janux Therapeutics
Biotechnology, N Torrey Pines Rd, San Diego, , 92037, California, 11099, United States, 51-200 Employees
Phone Number: 85********
Who is JANUX THERAPEUTICS
Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology ...
Read More
-
Headquarters: 11099 N Torrey Pines Rd, San Diego, California, 92037, United States
-
Date Founded: 2017
-
Employees: 51-200
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
-
CEO:
Sara Walsh
Email
Phone
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from JANUX THERAPEUTICS
Janux Therapeutics Org Chart and Mapping
Sara Walsh
Executive Administrative Assistant to the President and Chief Executive Officer
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Janux Therapeutics
Answer: Janux Therapeutics's headquarters are located at N Torrey Pines Rd, San Diego, , 92037, California, 11099, United States
Answer: Janux Therapeutics's phone number is 85********
Answer: Janux Therapeutics's official website is https://januxrx.com
Answer: Janux Therapeutics's revenue is $5 Million to $10 Million
Answer: Janux Therapeutics's SIC: 2836
Answer: Janux Therapeutics's NAICS: 541714
Answer: Janux Therapeutics has 51-200 employees
Answer: Janux Therapeutics is in Biotechnology
Answer: Janux Therapeutics contact info: Phone number: 85******** Website: https://januxrx.com
Answer: Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Januxs initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors have faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations. Janux is developing a broad pipeline with lead programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2), with all of its programs currently in the IND-enabling or discovery stage.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
CEO at Janux Therapeutics
Sara Walsh
Executive Administrative Assistant to the President and Chief Executive Officer
Sign in to CIENCE GO Data to uncover contact details
Free credits every month